Design and evaluation of dihydroisoquinolines as potent and orally bioavailable human cytomegalovirus inhibitors

  • Bioorg Med Chem Lett. 2000 Jul 3;10(13):1477-80. doi: 10.1016/s0960-894x(00)00265-1.
L Chan  1 ,  T Stefanac ,  N Turcotte ,  Z Hu ,  Y Chen ,  J Bédard ,  S May ,  H Jin
Affiliations
PMID: 10888336 DOI: 10.1016/s0960-894x(00)00265-1
Abstract

Following the identification of first pass metabolism issues with our recently described anti-HCMV compounds, the naphthyridines and isoquinolines, we have designed a class of novel metabolically stable and orally bioavailable anti-HCMV agents, the dihydroisoquinolines.